Investigational Drug Details
| Drug ID: | D349 |
| Drug Name: | Desflurane |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01189 |
| DrugBank Description: | Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anaesthesia. Volatile agents such as desflurane may activate GABA channels and hyperpolarize cell membranes. In addition, they may inhibit certain calcium channels and therefore prevent release of neurotransmitters and inhibit glutamate channels. Volatile anesthetics easily partition into cellular membranes and could expand the volume of the cell membrane and subsequently distort channels necessary for sodium ion flux and the development of action potentials necessary for synaptic transmission. Desflurane preconditions human myocardium against ischemia through activation of mitochondrial K(ATP) channels, adenosine A1 receptor, and alpha and beta adrenoceptors. |
| PubChem ID: | 42113 |
| CasNo: | 57041-67-5 |
| Repositioning for NAFLD: | Yes |
| SMILES: | FC(F)OC(F)C(F)(F)F |
| Structure: |
|
| InChiKey: | DPYMFVXJLLWWEU-UHFFFAOYSA-N |
| Molecular Weight: | 168.0378 |
| DrugBank Targets: | GABA-A receptor (anion channel); Glycine receptor subunit alpha-1; Glutamate receptor 1; Potassium voltage-gated channel subfamily A member 1; NADH-ubiquinone oxidoreductase chain 1; NA; ATP synthase subunit delta, mitochondrial |
| DrugBank MoA: | Desflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Desflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Desflurane also binds to and agonizes the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glycine receptors, and antagonizes the glutamate receptors. |
| DrugBank Pharmacology: | Desflurane is a general inhalation anesthetic. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential. |
| DrugBank Indication: | For use as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L2387 | NCT00700765 | COMPLETED | NO | 2008-01 | 2016-10-28 | Details | |
| L2647 | NCT01089192 | PHASE1 | COMPLETED | NO | 2010-10-14 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|